Energizer Personal Care inks licensing partnership with agency Brandgenuity
NEW YORK — Energizer Personal Care, which is a division of Energizer Holdings, has announced a partnership with New York-based licensing agency Brandgenuity LLC to extend the reach of its Hawaiian Tropic, Banana Boat and Playtex brands.
"At Energizer Personal Care, we strive to deliver high-quality products to our loyal consumers," stated Jim Alsante, group marketing director at Energizer Personal Care. "Playtex, Banana Boat and Hawaiian Tropic are three of our most powerful brands, and we’re thrilled to partner with Brandgenuity to bolster and deepen their reach. Brandgenuity has a proven, dynamic portfolio, and we are confident they are the best partner to deliver real results."
"We’re thrilled Energizer Personal Care has selected Brandgenuity to explore strategic and thoughtful licensing opportunities for these three iconic brands," added Jay Asher, partner at Brandgenuity. "We are looking forward to working together to extend into products that support the active healthy outdoor lifestyle and caring for baby."
Report: The Little Clinic to expand footprint with six new locations
CINCINNATI — Kroger is looking to open six additional Little Clinic locations within its stores in Ohio this summer and plans to expand its relationship with Ohio State University’s Wexner Medical Center, according to a local news report.
The clinic operator currently has seven Columbus-area locations inside select Kroger stores, but Kroger has indicated that it is opening the additional locations because of higher patient volume and demand from employers to curb rising healthcare costs, according to a report by Columbus Business First.
According to the report, the company is also expanding its referral and co-branding relationship with Wexner Medical Center, which started as a trial run in Lewis Center.
To read the entire article, click here.
FDA has collected more than $255 million in generic drug user fees
NEW YORK — The Food and Drug Administration’s Center for Drug Evaluation and Research has collected 84% of the fees it intends to collect this year under a law passed last year to collect user fees from generic drug members, according to a memo sent out to CDER staff Tuesday.
CDER director Janet Woodcock wrote that the FDA had collected more than $255 million under the Generic Drug User Fee Amendments to the 2012 Prescription Drug User Fee Act reauthorization. The agency plans to collect $299 million in fiscal year 2013.
In addition, the agency has hired 165 new CDER staff members, helped to make it easier to accurately calculate fees and made "significant strides" in reducing the backlog of generic drug approval applications.
"As we approach the one-year anniversary of the Generic Drug User Fee Amendments of 2012 (GDUFA), I would like to recognize the important accomplishments of those who have worked to launch this program," Woodcock wrote. "This has been a cross-cutting Center and Agency-wide effort led by Mary Beth Clarke, and involving staff and managers from the Office of Regulatory Affairs and most of CDER’s offices."
Woodcock wrote that the program would transition to a new project and governance structure similar to PDUFA, led by a new steering committee and focusing on enhancing the program and transforming the generic drug application review process.